Research ExplorerPublicationsThe challenge of valve-in-valve procedures in degenerated Mi...

The challenge of valve-in-valve procedures in degenerated Mitroflow bioprostheses and the advantage of using the JenaValve transcatheter heart valve

Standard

The challenge of valve-in-valve procedures in degenerated Mitroflow bioprostheses and the advantage of using the JenaValve transcatheter heart valve. / Conradi, Lenard; Kloth, Benjamin; Seiffert, Moritz; Schirmer, Johannes; Koschyk, Dietmar; Blankenberg, Stefan; Reichenspurner, Hermann; Diemert, Patrick; Treede, Hendrik.

In: EUROINTERVENTION, Vol. 10, No. 8, 12.2014, p. 990-994.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Conradi, L, Kloth, B, Seiffert, M, Schirmer, J, Koschyk, D, Blankenberg, S, Reichenspurner, H, Diemert, P & Treede, H 2014, 'The challenge of valve-in-valve procedures in degenerated Mitroflow bioprostheses and the advantage of using the JenaValve transcatheter heart valve', EUROINTERVENTION, vol. 10, no. 8, pp. 990-994. https://doi.org/10.4244/EIJV10I8A167

APA

Conradi, L., Kloth, B., Seiffert, M., Schirmer, J., Koschyk, D., Blankenberg, S., Reichenspurner, H., Diemert, P., & Treede, H. (2014). The challenge of valve-in-valve procedures in degenerated Mitroflow bioprostheses and the advantage of using the JenaValve transcatheter heart valve. EUROINTERVENTION, 10(8), 990-994. https://doi.org/10.4244/EIJV10I8A167

Vancouver

Conradi L, Kloth B, Seiffert M, Schirmer J, Koschyk D, Blankenberg S et al. The challenge of valve-in-valve procedures in degenerated Mitroflow bioprostheses and the advantage of using the JenaValve transcatheter heart valve. EUROINTERVENTION. 2014 Dec;10(8):990-994. https://doi.org/10.4244/EIJV10I8A167

Bibtex

@article{2e43a8961ceb48518f01ed0668761c09,
title = "The challenge of valve-in-valve procedures in degenerated Mitroflow bioprostheses and the advantage of using the JenaValve transcatheter heart valve",
abstract = "AIMS: Recently, the feasibility of valve-in-valve procedures using current first-generation transcatheter heart valves (THV) in cases of structural valve degeneration has been reported as an alternative to conventional open repeat valve replacement. By design, certain biological valve xenografts carry a high risk of coronary ostia occlusion due to lateral displacement of leaflets after valve-in-valve procedures. In the present report we aimed to prove feasibility and safety of transapical valve-in-valve implantation of the JenaValve THV in two cases of degenerated Mitroflow bioprostheses.METHODS AND RESULTS: We herein report two cases of successful transapical valve-in-valve procedures using a JenaValve THV implanted in Sorin Mitroflow bioprostheses for structural valve degeneration. Both patients were alive and in good clinical condition at 30 days from the procedure. However, increased transvalvular gradients were noted in both cases.CONCLUSIONS: Transcatheter valve-in-valve implantation of a JenaValve THV is a valid alternative for patients with degenerated Mitroflow bioprostheses of sufficient size and in the presence of short distances to the coronary ostia who are too ill for conventional repeat open heart surgery. Increased pressure gradients have to be expected and weighed against the disadvantages of other treatment options when planning such a procedure.",
keywords = "Aged, Aortic Valve Insufficiency/surgery, Bioprosthesis, Feasibility Studies, Heart Valve Prosthesis, Humans, Male, Prosthesis Design, Prosthesis Failure, Transcatheter Aortic Valve Replacement/methods",
author = "Lenard Conradi and Benjamin Kloth and Moritz Seiffert and Johannes Schirmer and Dietmar Koschyk and Stefan Blankenberg and Hermann Reichenspurner and Patrick Diemert and Hendrik Treede",
year = "2014",
month = dec,
doi = "10.4244/EIJV10I8A167",
language = "English",
volume = "10",
pages = "990--994",
journal = "EUROINTERVENTION",
issn = "1774-024X",
publisher = "EUROPA EDITION",
number = "8",

}

RIS

TY - JOUR

T1 - The challenge of valve-in-valve procedures in degenerated Mitroflow bioprostheses and the advantage of using the JenaValve transcatheter heart valve

AU - Conradi, Lenard

AU - Kloth, Benjamin

AU - Seiffert, Moritz

AU - Schirmer, Johannes

AU - Koschyk, Dietmar

AU - Blankenberg, Stefan

AU - Reichenspurner, Hermann

AU - Diemert, Patrick

AU - Treede, Hendrik

PY - 2014/12

Y1 - 2014/12

N2 - AIMS: Recently, the feasibility of valve-in-valve procedures using current first-generation transcatheter heart valves (THV) in cases of structural valve degeneration has been reported as an alternative to conventional open repeat valve replacement. By design, certain biological valve xenografts carry a high risk of coronary ostia occlusion due to lateral displacement of leaflets after valve-in-valve procedures. In the present report we aimed to prove feasibility and safety of transapical valve-in-valve implantation of the JenaValve THV in two cases of degenerated Mitroflow bioprostheses.METHODS AND RESULTS: We herein report two cases of successful transapical valve-in-valve procedures using a JenaValve THV implanted in Sorin Mitroflow bioprostheses for structural valve degeneration. Both patients were alive and in good clinical condition at 30 days from the procedure. However, increased transvalvular gradients were noted in both cases.CONCLUSIONS: Transcatheter valve-in-valve implantation of a JenaValve THV is a valid alternative for patients with degenerated Mitroflow bioprostheses of sufficient size and in the presence of short distances to the coronary ostia who are too ill for conventional repeat open heart surgery. Increased pressure gradients have to be expected and weighed against the disadvantages of other treatment options when planning such a procedure.

AB - AIMS: Recently, the feasibility of valve-in-valve procedures using current first-generation transcatheter heart valves (THV) in cases of structural valve degeneration has been reported as an alternative to conventional open repeat valve replacement. By design, certain biological valve xenografts carry a high risk of coronary ostia occlusion due to lateral displacement of leaflets after valve-in-valve procedures. In the present report we aimed to prove feasibility and safety of transapical valve-in-valve implantation of the JenaValve THV in two cases of degenerated Mitroflow bioprostheses.METHODS AND RESULTS: We herein report two cases of successful transapical valve-in-valve procedures using a JenaValve THV implanted in Sorin Mitroflow bioprostheses for structural valve degeneration. Both patients were alive and in good clinical condition at 30 days from the procedure. However, increased transvalvular gradients were noted in both cases.CONCLUSIONS: Transcatheter valve-in-valve implantation of a JenaValve THV is a valid alternative for patients with degenerated Mitroflow bioprostheses of sufficient size and in the presence of short distances to the coronary ostia who are too ill for conventional repeat open heart surgery. Increased pressure gradients have to be expected and weighed against the disadvantages of other treatment options when planning such a procedure.

KW - Aged

KW - Aortic Valve Insufficiency/surgery

KW - Bioprosthesis

KW - Feasibility Studies

KW - Heart Valve Prosthesis

KW - Humans

KW - Male

KW - Prosthesis Design

KW - Prosthesis Failure

KW - Transcatheter Aortic Valve Replacement/methods

U2 - 10.4244/EIJV10I8A167

DO - 10.4244/EIJV10I8A167

M3 - SCORING: Journal article

C2 - 24647151

VL - 10

SP - 990

EP - 994

JO - EUROINTERVENTION

JF - EUROINTERVENTION

SN - 1774-024X

IS - 8

ER -